MedTech & Diagnostics

STAAR Surgical Executive Compensation (FY25)

Name: STAAR Surgical (STAA) executive compensation
Creator: Velarion
License: https://intel.velarion.ai/terms

STAA · Executive and director compensation, fiscal 2022 to 2025

Chief executive, fiscal 2025

◇

Stephen Farrell

Median of the other named officers

$2,639,082

6 officers, excluding the chief executive

Latest say-on-pay support

April 20, 2026

Chief executive pay ratio

◇

To the median employee

Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The paid brief on STAAR Surgical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

Data as of October 19, 2026Latest filing (8-K): June 22, 2026

16 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

STAAR Surgical brief$1,500Get the executive brief

Velarion Member, one year

336 figures on this page: 325 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

Frequently asked questions

Answers drawn from the data on this page.

Who is STAAR Surgical's chief executive and what were they paid?

Stephen Farrell, Chief Executive Officer, received $7,522,385 in total compensation for fiscal 2025.

What was STAAR Surgical's say-on-pay result?

For fiscal 2025, shareholders backed the say-on-pay proposal with 96.3% of votes cast including abstentions in favor at the meeting held April 20, 2026.

Which companies are in STAAR Surgical's peer group?

Companies named in the disclosed peer group include Alphatec Holdings, Inc., Artivion, Inc., AtriCure, Inc., Avanos Medical, Inc. and AxoGen, Inc., among others.

What is STAAR Surgical's chief executive pay ratio?

For fiscal 2025, the company reported a chief executive pay ratio of 97:1, against median employee compensation of $89,344.

Executive compensation

Every element reported for each named executive officer, by fiscal year.

Fiscal 2022

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Caren Mason Former President and Chief Executive Officer Departed during or after this year	◇	◇	◇	◇	—	—	◇	◇
Patrick Williams Chief Financial Officer	◇	◇	◇	◇	—	—	◇	◇
Scott Barnes Chief Medical Officer	◇	◇	◇	◇	—	—	◇	◇
Keith Holliday Chief Technology Officer	◇	◇	◇	◇	—	—	◇	◇
James Francese Senior Vice President, Commercial Commercial Operations Asia	◇	◇	◇	◇	—	—	◇	◇

Fiscal 2023

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Thomas Frinzi Former President and Chief Executive Officer	◇	—	◇	◇	◇	—	◇	◇
Warren Foust President and Chief Operating Officer	◇	—	◇	◇	◇	—	◇	◇
Patrick Williams Former Chief Financial Officer	◇	—	◇	◇	◇	—	◇	◇

Fiscal 2024

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Thomas Frinzi President and Chief Executive Officer	◇	—	◇	◇	—	—	◇	◇
Warren Foust Chief Operating Officer	◇	—	◇	◇	—	—	◇	◇
Patrick Williams Chief Financial Officer	◇	—	◇	◇	—	—	◇	◇
Magda Michna Chief Clinical, Regulatory and Medical Affairs Officer	◇	◇	◇	◇	—	—	◇	◇
Nathaniel Sisitsky General Counsel and Corporate Secretary	◇	—	◇	◇	—	—	◇	◇

Fiscal 2025

Officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Stephen Farrell Chief Executive Officer	◇	—	◇	—	—	—	◇	◇
Warren Foust President and Chief Operating Officer	◇	◇	◇	—	◇	—	◇	◇
Nathaniel Sisitsky Chief Legal Officer and Corporate Secretary	◇	◇	◇	—	◇	—	◇	◇
Magda Michna Chief Development Officer	◇	—	◇	—	◇	—	◇	◇
Deborah Andrews Chief Financial Officer	◇	—	◇	—	◇	—	◇	◇
Thomas Frinzi Former President and Chief Executive Officer Departed during or after this year	◇	—	—	—	—	—	◇	◇
Patrick Williams Former Chief Financial Officer Departed during or after this year	◇	—	—	—	—	—	◇	◇

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.

Fiscal 2025

Officer	Award	Grant date	Threshold units	Target units	Units granted	Maximum units	Exercise price	Grant date fair value
Deborah Andrews	PSU	◇	◇	◇	—	◇	—	◇
Deborah Andrews	RSU	◇	—	—	◇	—	—	◇
Magda Michna	RSU	◇	—	—	◇	—	—	◇
Magda Michna	RSU	◇	—	—	◇	—	—	◇
Magda Michna	PSU	◇	◇	◇	—	◇	—	◇
Magda Michna	PSU	◇	◇	◇	—	◇	—	◇
Nathaniel Sisitsky	RSU	◇	—	—	◇	—	—	◇
Nathaniel Sisitsky	PSU	◇	◇	◇	—	◇	—	◇
Nathaniel Sisitsky	PSU	◇	◇	◇	—	◇	—	◇
Nathaniel Sisitsky	RSU	◇	—	—	◇	—	—	◇
Stephen C. Farrell	RSU	◇	—	—	◇	—	—	◇
Stephen C. Farrell	PSU	◇	◇	◇	—	◇	—	◇
Warren Foust	RSU	◇	—	—	◇	—	—	◇
Warren Foust	RSU	◇	—	—	◇	—	—	◇
Warren Foust	PSU	◇	◇	◇	—	◇	—	◇
Warren Foust	PSU	◇	◇	◇	—	◇	—	◇

Fiscal 2022, 2024 are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.

As disclosed at fiscal 2025 year end

Officer	Award	Unvested units	Market value of unvested units	Exercise price	Expires
Magda Michna	Option	◇	—	◇	5/7/2033
	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	3/11/2034
Warren Foust	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	Option	◇	—	◇	3/11/2034
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	5/7/2033
Thomas Frinzi	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
Nathaniel Sisitsky	Option	◇	—	◇	3/11/2034
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	RSU	◇	◇	—	—
	Option	◇	—	◇	12/10/2033
Stephen Farrell	RSU	◇	◇	—	—
	PSU	◇	◇	—	—
	RSU	◇	◇	—	—
Deborah Andrews	RSU	◇	◇	—	—
	PSU	◇	◇	—	—

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.

Deborah Andrews

Chief Financial Officer · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Equity acceleration on change in control	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Excise tax treatment	◇
Non-solicit period	◇
Clawback	◇

Magda Michna

Chief Development Officer · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇
Clawback	◇

Nathaniel Sisitsky

Chief Legal Officer and Corporate Secretary · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇
Clawback	◇

Patrick Williams

Former Chief Financial Officer · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇

Stephen Farrell

Chief Executive Officer · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇
Clawback	◇

Warren Foust

President and Chief Operating Officer · Change-in-control agreement

Severance multiple	◇
Change-in-control multiple	◇
Equity acceleration on change in control	◇
Benefits continuation on change in control	◇
Benefits continuation	◇
Non-solicit period	◇

Director compensation

What each non-employee director was paid.

Fiscal 2025

Director	Fees earned in cash	Stock awards	Option awards	Non-equity incentive	Pension and deferred earnings	All other compensation	Total
Wei Jiang	◇	◇	—	—	—	◇	◇
Lilian Y. Zhou	◇	—	◇	—	—	◇	◇
Elizabeth Yeu, M.D	◇	◇	◇	—	—	—	◇
Louis E. Silverman	◇	◇	◇	—	—	—	◇
Arthur C. Butcher	◇	◇	◇	—	—	—	◇
Aimee S. Weisner	◇	—	—	—	—	—	◇

Christopher M. Wang, Richard T. LeBuhn, Neal C. Bradsher, K. Peony Yu, M.D, Thomas G. Frinzi and Stephen C. Farrell served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.

Earlier years are included in the PDF.

A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.

Board cash retainer	◇
Board equity retainer	◇
Total board retainer	◇
Lead independent director premium	◇
Audit committee chair	◇
Audit committee member	◇
Compensation committee chair	◇
Compensation committee member	◇
Nominating and governance chair	◇
Nominating and governance member	◇

Equity is delivered as Restricted Stock or Stock Options (director's choice).

Stock ownership guideline: 3x base annual cash retainer (directors); 3x annual base salary (CEO)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Fiscal 2025

Alphatec Holdings, Inc. ATEC
Artivion, Inc. AORT
AtriCure, Inc. ATRC
Avanos Medical, Inc. AVNS
AxoGen, Inc. AXGN
Glaukos Corp. GKOS
Inari Medical, Inc. NARI
Inspire Medical Systems, Inc. INSP
iRhythm Technologies, Inc. IRTC
LeMaitre Vascular, Inc. LMAT
Merit Medical Systems, Inc. MMSI
Penumbra, Inc. PEN
RxSight, Inc. RXST
Tandem Diabetes Care, Inc. TNDM
UFP Technologies, Inc. UFPT

Say-on-pay history

Shareholder support for the compensation program, by year.

Year	Meeting	Support	Votes for	Votes against	Abstentions
2025	April 20, 2026	=	◇	◇	◇
2024	June 18, 2025	=	◇	◇	◇
2023	June 20, 2024	=	◇	◇	◇
2022	June 15, 2023	=	◇	◇	◇
2021	June 16, 2022	=	◇	◇	◇
2020	June 24, 2021	=	◇	◇	◇
2019	July 30, 2020	=	◇	◇	◇
2018	June 20, 2019	=	◇	◇	◇
2017	June 14, 2018	=	◇	◇	◇
2016	June 13, 2017	=	◇	◇	◇
2015	June 24, 2016	=	◇	◇	◇

Chief executive pay ratio

As calculated and reported by the company.

Ratio

◇

Median employee compensation

◇

Chief executive total compensation

◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”

- Stephen Farrell (Chief Executive Officer), FY2025 total compensation $7,522,385 (base salary $580,000) [exec_comp, SEC accession 0000718937-26-000015, filed 2026-05-04]

What this page does not include

Everything above is a fact STAAR Surgical disclosed, and it is free. Everything below is our analysis of those facts, and it is not.

Peer benchmarking

Where STAAR Surgical sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.

Executive Compensation Report — $1,500

Written compensation analysis

A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.

Executive Compensation Report — $1,500

Board and governance analysis

Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.

Board Governance Report — $499

Realizable pay

What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.

Velarion Intelligence

Adviser switching and vote outcomes

Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.

Inquire about access

Multiple companies at once

Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.

Velarion Intelligence

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.

336 figures on this page: 325 cited to the filing that reported them, 11 calculated from figures it prints.

325 cited to the filing

11 calculated from the filing

Documents cited

8-K, filed June 22, 2026
0000718937-26-000029
Proposal 4 : To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes
DEF 14A, filed May 4, 2026
0000718937-26-000015
Compensation Tables · Compensation of Directors · Pay Ratio Disclosure
8-K, filed June 18, 2025
0000950170-25-087967
Proposal 3 : To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: Number of Shares For Against Abstain Broker Non-Votes
DEF 14A, filed April 24, 2025
0000950170-25-058174
Summary Compensation Table
8-K, filed June 21, 2024
0000950170-24-076303
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 24, 2024
0000950170-24-047635
Summary Compensation Table
EX-10, filed December 29, 2023
0000950170-24-020572
8-K, filed June 16, 2023
0000950170-23-028687
Item 5.07 Submission of Matters to a Vote of Security Holders
DEF 14A, filed April 26, 2023
0000950170-23-014790
Compensation Tables
8-K, filed June 17, 2022
0001564590-22-023566
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 25, 2021
0001564590-21-034584
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed August 3, 2020
0001564590-20-035237
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 21, 2019
0001564590-19-023002
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 14, 2018
0001144204-18-034262
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 14, 2017
0001144204-17-032385
Item 5.07 Submission of Matters to a Vote of Security Holders
8-K, filed June 27, 2016
0001144204-16-109967
Item 5.07 Submission of Matters to a Vote of Security Holders

Cite this data

This page is free to cite. Attribution we ask for:

Velarion, “STAAR Surgical executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/STAA (accessed 2026).

Short form: data: Velarion

The paid brief for STAAR Surgical

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.

$1,500 for the Executive Compensation Report. Both reports for $2,400.

Get the executive brief Get the board briefNo account needed.

16 filings cited on this page

Method: intel.velarion.ai/methodology

A report that fails to generate is refunded in full

Published by Velarion Company Intelligence

Embed this data

A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.

The headline figures, each with its citation.

<iframe src="https://intel.velarion.ai/comp/STAA/embed" width="560" height="480" style="border:1px solid #d8dee8;border-radius:10px" loading="lazy" title="STAAR Surgical executive compensation, from Velarion"></iframe>

Connect an AI assistant

Ask your own assistant about STAAR Surgical and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

{
  "mcpServers": {
    "velarion": {
      "type": "http",
      "url": "https://api.velarion.ai/mcp"
    }
  }
}

Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & Diagnostics CEO pay ratio — MedTech & Diagnostics Say-on-pay support — MedTech & Diagnostics

Peers STAAR Surgical discloses

The companies named in STAA's own disclosed peer group.

Alphatec Holdings, Inc.Artivion, Inc.AtriCure, Inc.Avanos Medical, Inc.AxoGen, Inc.Glaukos Corp.Inari Medical, Inc.Inspire Medical Systems, Inc.iRhythm Technologies, Inc.LeMaitre Vascular, Inc.Merit Medical Systems, Inc.Penumbra, Inc.RxSight, Inc.Tandem Diabetes Care, Inc.UFP Technologies, Inc.

Terms on this page

Say-on-Pay Vote CEO Pay Ratio Median Employee Compensation All companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data

APA

Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854

BibTeX

@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}

More on STAAR Surgical

Frequently asked questions

Executive compensation

Equity awards granted

Outstanding awards

Severance and change in control

Director compensation

Director fee schedule

Disclosed peer group

Say-on-pay history

Chief executive pay ratio

Velarion Pro: every company page, peer tools and exports, one seat

What this page does not include

Citations

Documents cited

The paid brief for STAAR Surgical

MedTech & Diagnostics rankings

Peers STAAR Surgical discloses

Terms on this page